GSK Inks $650M Deal with Vesalius Therapeutics for Parkinson’s Disease Small Molecule Drug

Nov 12, 2024 21:49 CST Updated 21:49

GSK

Pharmaceutical R&D Manufacturer

Vesalius Therapeutics

Disease Treatment Drug Developer

November 12,Cambridge, Massachusetts – Vesalius Therapeutics, a company that has pioneered a revolutionary platform for providing breakthrough treatments for common diseases, announced a multi-target strategic alliance with GSK to discover and develop new therapies for Parkinson’s disease and another undisclosed neurodegenerative disease. Vesalius will utilize its platform to identify new intervention points for Parkinson’s disease.intervention points) and another indication for neurodegenerative diseases, GSK will have the right to advance projects targeting these new intervention points. GSK will also receive fromVesaliusAcquire global development and commercial rights to a preclinical small molecule project initially focused on Parkinson's disease.Parkinson's Disease. Flagship Pioneering invested $75 million to incubate Vesalius Therapeutics in March 2022.

Under the terms of the agreement, GSK will be responsible for advancing Vesalius' preclinical small molecule new drug, with the initial focus on Parkinson's disease, and has the right to advance programs targeting new intervention points for Parkinson's disease and another neurodegenerative disease.GSK will control all development and commercialization.Vesalius Therapeutics will receive an upfront payment and equity investment of $80 million and is eligible for up to $570 million in potential preclinical, development, and commercial milestone payments, as well as tiered royalties on preclinical small molecule programs.In addition, Vesalius is eligible for preclinical, development, and commercial milestone payments, as well as tiered royalties on each new intervention point generated from the multi-target deal.The Potential Total Payment for Each New Intervention Point Remains Undisclosed。

Vesalius is redefining common diseases to identify previously unrecognized patient populations who may respond positively to treatments targeting new intervention points. The company leverages large-scale human genetics, genomics, induced pluripotent stem cell (iPSC) models, and artificial intelligence to uncover causal biology and determine the optimal intervention points for new therapies. Vesalius' platform represents a revolutionary approach to drug development for common diseases, driving the creation of novel therapies and paradigms aimed at increasing the success rate of the drug development process.

Vesalius Therapeutics Executive Chairman and Interim CEO, Dr. John Mendlein, said:"Many diseases that impact patients globally have a diagnosis, but in fact, they encompass a variety of different diseases, each with distinct biological causes. Vesalius is redefining how we understand and treat common diseases, including autoimmune diseases, diabetes, and neurological disorders, including but not limited to Parkinson's disease. Parkinson’s disease has significant unmet needs, and the number of new intervention points for patients and their families has hardly changed in 60 years since the introduction of the first levodopa medication. At the core of our alliance with GSK is our shared belief that targeting the root causes of common diseases like Parkinson’s is key to developing breakthrough treatments faster and with a higher probability of success."

Kaivan Khavandi, M.D., Global Head of Respiratory/Immunology R&D at GSK, stated:"We are withVesaliusThe alliance highlights GSK's commitment to discovering and developing disease-modifying therapies in areas of significant unmet need. Using the Vesalius platform to understand the underlying drivers of such neurodegenerative diseases and select the best therapeutic interventions underscores our focus on leveraging advanced technologies to identify and target the root causes of diseases."

Follow the official account below to see the world!